Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric J Small

Showing results (141-150 of 361) with videos related to

Pageof 37
Sort By:
Cancer|September 24, 2010
A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer: results from Cancer and Leukemia Group B Study 90006Joel Picus, Susan Halabi, W Kevin Kelly, et al.
Urologic Oncology|October 2, 2010
Effect of the somatostatin analog octreotide acetate on circulating insulin-like growth factor-1 and related peptides in patients with non-metastatic castration-resistant prostate cancer: results of a phase II studyTerence W Friedlander, Vivian K Weinberg, Eric J Small, et al.
Contemporary Clinical Trials Communications|October 2, 2018
A bilingual, Internet-based, targeted advertising campaign for prostate cancer clinical trials: Assessing the feasibility, acceptability, and efficacy of a novel recruitment strategyCelia P Kaplan, Adam Siegel, Yan Leykin, et al.
EJNMMI Research|September 21, 2017
Optimal MRI sequences for <sup>68</sup>Ga-PSMA-11 PET/MRI in evaluation of biochemically recurrent prostate cancerSpencer T Lake, Kirsten L Greene, Antonio C Westphalen, et al.
JCO Clinical Cancer Informatics|May 18, 2022
Mobile Clinical Trial Matching Technology in Medical Oncology Clinic: A Pilot Feasibility StudyHala T Borno, Li Zhang, Sylvia Zhang, et al.
Cancer|June 20, 2007
Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients : randomized phase 2 study of ixabepilone or mitoxantrone and prednisoneJonathan E Rosenberg, Vivian K Weinberg, W Kevin Kelly, et al.
The Canadian Journal of Urology|December 22, 2015
Optimal timing of sipuleucel-T treatment in metastatic castration-resistant prostate cancerE David Crawford, Daniel P Petrylak, Celestia S Higano, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 23, 2014
Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancerSusan Halabi, Chen-Yen Lin, W Kevin Kelly, et al.
International Journal of Radiation Oncology, Biology, Physics|November 27, 2007
Tumor volume changes on 1.5 tesla endorectal MRI during neoadjuvant androgen suppression therapy for higher-risk prostate cancer and recurrence in men treated using radiation therapy results of the phase II CALGB 9682 studyAnthony V D'Amico, Susan Halabi, Clare Tempany, et al.
BJU International|February 1, 2008
A pilot dose-escalation study of the effects of nordihydroguareacetic acid on hormone and prostate specific antigen levels in patients with relapsed prostate cancerCharles J Ryan, Andrea H Harzstark, Jonathan Rosenberg, et al.
Pageof 37

Showing results (141-150 of 361) with videos related to

Sort By:
Pageof 37
Cancer|September 24, 2010
A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer: results from Cancer and Leukemia Group B Study 90006Joel Picus, Susan Halabi, W Kevin Kelly, et al.
Urologic Oncology|October 2, 2010
Effect of the somatostatin analog octreotide acetate on circulating insulin-like growth factor-1 and related peptides in patients with non-metastatic castration-resistant prostate cancer: results of a phase II studyTerence W Friedlander, Vivian K Weinberg, Eric J Small, et al.
Contemporary Clinical Trials Communications|October 2, 2018
A bilingual, Internet-based, targeted advertising campaign for prostate cancer clinical trials: Assessing the feasibility, acceptability, and efficacy of a novel recruitment strategyCelia P Kaplan, Adam Siegel, Yan Leykin, et al.
EJNMMI Research|September 21, 2017
Optimal MRI sequences for <sup>68</sup>Ga-PSMA-11 PET/MRI in evaluation of biochemically recurrent prostate cancerSpencer T Lake, Kirsten L Greene, Antonio C Westphalen, et al.
JCO Clinical Cancer Informatics|May 18, 2022
Mobile Clinical Trial Matching Technology in Medical Oncology Clinic: A Pilot Feasibility StudyHala T Borno, Li Zhang, Sylvia Zhang, et al.
Cancer|June 20, 2007
Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients : randomized phase 2 study of ixabepilone or mitoxantrone and prednisoneJonathan E Rosenberg, Vivian K Weinberg, W Kevin Kelly, et al.
The Canadian Journal of Urology|December 22, 2015
Optimal timing of sipuleucel-T treatment in metastatic castration-resistant prostate cancerE David Crawford, Daniel P Petrylak, Celestia S Higano, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 23, 2014
Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancerSusan Halabi, Chen-Yen Lin, W Kevin Kelly, et al.
International Journal of Radiation Oncology, Biology, Physics|November 27, 2007
Tumor volume changes on 1.5 tesla endorectal MRI during neoadjuvant androgen suppression therapy for higher-risk prostate cancer and recurrence in men treated using radiation therapy results of the phase II CALGB 9682 studyAnthony V D'Amico, Susan Halabi, Clare Tempany, et al.
BJU International|February 1, 2008
A pilot dose-escalation study of the effects of nordihydroguareacetic acid on hormone and prostate specific antigen levels in patients with relapsed prostate cancerCharles J Ryan, Andrea H Harzstark, Jonathan Rosenberg, et al.
Pageof 37